Regulation
Labcorp’s advanced melanoma CDx secures FDA approval
Labcorp received FDA approval for a companion diagnostic (CDx) test that detects BRAF V600E and V600K mutations in melanoma patients to identify candidates for BRAF inhibitor therapy. The test enables treatment selection for eligible patients.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network